Track topics on Twitter Track topics that are important to you
SAN FRANCISCO, Aug. 11, 2015 (GLOBE NEWSWIRE) -- Invuity, Inc. (NASDAQ:IVTY), a medical technology company, today reported financial results for the second quarter and six-months ended June 30, 2015.
Q2 2015 Highlights
Revenue was $4.7 million in the second quarter of 2015, compared to $2.8 million in the second quarter of 2014 and $4.4 million in the first quarter of 2015. Revenue in the second quarter of 2015 would have totaled $5.0 million, without the impact of an approximately $300,000 reversal of revenue that was originally recorded in the fourth quarter of 2014.
For the first six months of 2015, revenue was $9.2 million, up 85 percent from revenue of $5.0 million in the first six months of 2014.
"Invuity has the unique opportunity to further expand its platform technology to enable new and emerging surgical procedures," said President and CEO Philip Sawyer. "We have built strong commercial momentum in our initial clinical areas and will continue to deliver devices and technologies that address additional specialties and new high volume procedures."
Gross margin for the second quarter and first six months of 2015 was 59 percent and 60 percent, respectively, compared to 55 percent and 59 percent for the same periods in 2014.
Total operating expenses for the 2015 second quarter and first six months were $11.7 million and $22.5 million, respectively, compared to $6.6 million and $12.4 million in the prior year periods.
The net loss for the second quarter of 2015 was $9.3 million, or $3.20 loss per share, compared to a net loss of $5.5 million, or $8.40 loss per share, for the second quarter of 2014. The net loss for the first half of 2015 was $18.4 million, or $10.11 loss per share, compared to $10.2 million, or $15.75 loss per share, for the first half of 2014.
The Company's balance sheet as of June 30, 2015, showed total cash and cash equivalents of $65.8 million, including proceeds from the IPO in June.
Invuity's management will discuss the Company's financial results for the second quarter and six months ended June 30, 2015, and provide a general business update during a conference call beginning at 5:00 p.m. Eastern Time today, August 11, 2015. To join the live call, participants may dial 1-855-539-0900 (U.S.) or 1-412-455-6044 (International). To listen to the live call via Invuity's website, go to www.invuity.com, in the Events & Presentations section. A webcast replay of the call will be available following the conclusion of the call for a period of 90 days in the Events & Presentations section of the website.
Invuity, Inc. is a medical technology company focused on developing and marketing advanced photonics devices to improve the ability of surgeons to illuminate and visualize the surgical cavity during open minimally invasive and minimal access surgery. The company's patented Intelligent Photonics™ technology enables enhanced surgical precision, efficiency and safety by providing superior visualization. Clinical applications include breast and thyroid oncology, plastic reconstructive, spine, orthopedic, cardiothoracic and general surgery among others. Invuity is headquartered in San Francisco, CA. For more information, visit www.invuity.com.
This announcement contains forward-looking statements that involve risks and uncertainties, including statements regarding market opportunities and potential results from future new initiatives. Actual results could differ materially from those projected in the forward-looking statements as a result of certain risk factors, including, but not limited to: fluctuations in demand or failure to gain market acceptance for the Company's devices; the Company's ability to demonstrate to and gain approval from hospitals to use the Company's devices; the highly competitive business environment for surgical medical devices; the Company's ability to sell its devices at prices that support its current business strategies; difficulty forecasting future financial performance; protection of the Company's intellectual property; and compliance with necessary regulatory clearances or approvals. The Company undertakes no obligation to update the forward-looking information in this release. More information about potential factors that could affect the Company's business and financial results is included in its filings with the Securities and Exchange Commission, including, without limitation, under the captions: "Management's Discussion and Analysis of Financial Condition and Results of Operations," and "Risk Factors," which are on file with the Securities and Exchange Commission.
Condensed Statements of Operations
(In thousands, except share and per share amounts)
Three Months Ended
Six Months Ended
|Revenue||$ 4,747||$ 2,816||$ 9,189||$ 4,970|
|Cost of goods sold||1,936||1,280||3,668||2,027|
|Selling, general and administrative||9,820||5,339||18,743||9,913|
|Research and development||1,857||1,310||3,757||2,513|
|Total operating expenses||11,677||6,649||22,500||12,426|
|Loss from operations||(8,866)||(5,113)||(16,979)||(9,483)|
|Interest and other income (expense), net||24||9||(526)||37|
|Net loss||$ (9,346)||$ (5,456)||$ (18,378)||$ (10,168)|
|Net loss per common share, basic and diluted||$ (3.20)||$ (8.40)||$ (10.11)||$ (15.75)|
|Weighted-average shares used to compute net loss per common share, basic and diluted||2,919,823||649,511||1,817,673||645,681|
as of June 30, 2015 (unaudited)
(In thousands, except share and per share amounts)
|Cash and cash equivalents||$ 65,755||$ 6,048|
|Accounts receivable, net||3,237||2,798|
|Prepaid expenses and other current assets||1,115||2,486|
|Total current assets||74,933||15,603|
|Property and equipment, net||9,037||8,541|
|Other non-current assets||--||55|
|Total assets||$ 85,095||$ 25,324|
|Liabilities, Convertible Preferred Stock and Stockholders' Equity (Deficit)|
|Accounts payable||$ 2,022||$ 1,075|
|Accrued and other current liabilities||5,094||4,162|
|Total current liabilities||7,116||5,237|
|Convertible preferred stock warrant liability||--||136|
|Long-term debt—related party||14,418||9,347|
|Commitments and contingencies|
|Convertible preferred stock, $0.001 par value—0 and 6,207,320 shares authorized at June 30, 2015 and December 31, 2014, respectively; 0 and 6,056,403 shares issued and outstanding at June 30, 2015 and December 31, 2014, respectively||--||73,755|
|Stockholders' equity (deficit):|
|Preferred stock, $0.001 par value—10,000,000 and no shares authorized at June 30, 2015 and December 31, 2014, respectively; no shares issued and outstanding at June 30, 2015 and December 31, 2014||--||--|
|Common stock, $0.001 par value—100,000,000 and 9,189,189 shares authorized at June 30, 2015 and December 31, 2014, respectively; 13,305,015 and 711,249 shares issued and outstanding at June 30, 2015 and December 31, 2014, respectively||13||1|
|Additional paid-in capital||147,132||2,209|
|Total stockholders' equity (deficit)||60,730||(65,827)|
|Total liabilities, convertible preferred stock and stockholders' equity (deficit)||$ 85,095||$ 25,324|
CONTACT: Media: Miranda Duncan Waggener Edstrom 415-342-9430 email@example.com Investors: Matt Clawson Pure Communications 949-370-8500 firstname.lastname@example.orgNEXT ARTICLE
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...